In an article titled “Empagliflozin’s effects independent of CVD risk factors,” published Sept. 27, 2017, the proportion of patients who achieved control of HbA1c, LDL cholesterol, and blood pressure at baseline in the empagliflozin group was misstated. It was 12.6%.
MORBIDITY AND MORTALITY WEEKLY REPORT A faster diagnostic tool for Zika virus infection than ...
AT THE ANNUAL MEETING OF AADE SAN DIEGO (FRONTLINE MEDICAL NEWS) – Assessing the ...
EXPERT ANALYSIS FROM AAP 16 SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – Integrating pediatric mental ...
